Management of Stage 2 Hypertension

Indications for Combination Therapy

The European Society of Cardiology recommends combination therapy for patients with confirmed stage 2 hypertension (≥140 mmHg systolic) to achieve a target blood pressure of 120-129 mmHg systolic, as monotherapy alone achieves blood pressure control in only a minority of patients 1, 3
The American College of Cardiology suggests that combination therapy is necessary for most patients with confirmed hypertension ≥140/90 mmHg, as young age requires investigation for secondary causes of hypertension, particularly in non-obese individuals 1, 2

The European Society of Cardiology guidelines recommend combining a RAS blocker (ACE inhibitor or ARB) with a dihydropyridine calcium channel blocker as a preferred first-line combination, providing complementary mechanisms of action and additive blood pressure-lowering effects 1, 3
The American College of Cardiology recommends using a dihydropyridine calcium channel blocker (such as amlodipine 5 mg daily) in combination with an ACE inhibitor (such as lisinopril), as this combination provides synergistic blood pressure-lowering effects 2, 4

If a calcium channel blocker is contraindicated or not tolerated, the European Society of Cardiology recommends adding a thiazide or thiazide-like diuretic (such as chlorthalidone 12.5 mg or hydrochlorothiazide 12.5 mg daily), as the combination of an ACE inhibitor with a thiazide diuretic has demonstrated synergistic blood pressure-lowering effects 1, 2

The European Society of Cardiology recommends aiming for a systolic blood pressure of 120-129 mmHg, provided treatment is well tolerated, to reduce cardiovascular risk 1
Blood pressure control should be achieved within 3 months of initiating or adjusting therapy, and patients should be monitored regularly to assess treatment efficacy and potential adverse effects 5

The European Society of Cardiology and the American College of Cardiology recommend avoiding the combination of two RAS blockers (e.g., adding an ARB to lisinopril), as this increases adverse effects including hyperkalemia and acute kidney injury without additional cardiovascular benefit 1, 2
Given the patient's young age, it is essential to assess for secondary hypertension causes, such as renal artery stenosis, primary aldosteronism, or obstructive sleep apnea, before assuming essential hypertension 1